Literature DB >> 7495668

Endothelin receptor antagonism.

T J Opgenorth1.   

Abstract

Following the original report by Yanagisawa et al. (1988) more than 7 years ago, compelling evidence that ET plays an important role in the local regulation of smooth muscle tone and cell growth has been reported. In addition, many studies point to a significant role for endothelin in nonvascular function. The investigation of the endothelin system has been greatly advanced in the last 2 to 3 years through significant advances in the development of potent and selective ET receptor antagonists. These agents have proven to be essential tools for elucidating the biological significance of the ET system, leading to the realization that antagonism of the ET system may have significant therapeutic potential. As emphasized in this review, the importance of chronic blockade of the ET system may be a critical aspect of future research in this exciting area. Confounding issues remain the lack of information about the role of the ETB receptor, the apparent pharmacological evidence for additional ET receptor subtypes, and species variation in the tissue distribution of ET isoforms and receptor subtypes. Along with the greater ability to understand the endothelin system provided by potent and selective pharmacological agents, is the important contribution of modern molecular biology techniques, highlighted by the insights gained from recent reports of results from ET gene disruption studies. Kurihara et al. (1994) found that ET-1-deficient homozygous mice die at birth of apparent respiratory failure secondary to severe craniofacial abnormalities. Subsequently, Yanagisawa's laboratory has presented and published a series of complementary gene disruption studies. First, Hosoda et al. (1994) demonstrated remarkably, that ETA receptor knockout mice bear morphological abnormalities nearly identical to ET-1 knockout mice. Second, they found that disruption of the ET-3 peptide and ETB receptor genes result in homozygous mice that share identical phenotypic traits (i.e., coloration changes and aganglionic megacolon) which are similar to a previously known natural mutation, the Piebald-Lethal mouse (Hosoda et al., 1994; Baynash et al., 1994). This phenotype has a human corollary known as Hirschsprung's Disease and it is now known that the disease, though multigenic, results from a missense mutation of the ETB receptor gene in some individuals (Puffenberger et al., 1994). Taken together these data indicate that the endothelin system is essential to correct embryonic neural crest development, a completely novel finding within the superfamily of guanine-protein-linked receptors.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495668     DOI: 10.1016/s1054-3589(08)60665-1

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN: 1054-3589


  12 in total

1.  Pharmacological characterization of endothelin receptor subtypes in the guinea-pig prostate gland.

Authors:  W A Lau; S L Cox; J N Pennefather; F J Mitchelson
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

2.  Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.

Authors:  Sun-Jin Kim; Jang Seong Kim; Seung Wook Kim; Seok Joong Yun; Junqin He; Emily Brantley; Dominic Fan; Panja Strickner; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

3.  Endothelin: Ominous Player in Breast Cancer.

Authors:  Anuradha Ratna; Salil K Das
Journal:  J Cancer Clin Trials       Date:  2015-10-12

4.  Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.

Authors:  Sun-Jin Kim; Jang Seong Kim; Seung Wook Kim; Emily Brantley; Seok Joong Yun; Junqin He; Marva Maya; Fahao Zhang; Qiuyu Wu; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Neoplasia       Date:  2011-02       Impact factor: 5.715

5.  Chronic endothelin-1 treatment leads to heterologous desensitization of insulin signaling in 3T3-L1 adipocytes.

Authors:  K I Ishibashi ; T Imamura; P M Sharma; J Huang; S Ugi; J M Olefsky
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

6.  Phosphatidylinositol 4,5-bisphosphate reverses endothelin-1-induced insulin resistance via an actin-dependent mechanism.

Authors:  Andrew B Strawbridge; Jeffrey S Elmendorf
Journal:  Diabetes       Date:  2005-06       Impact factor: 9.461

7.  Development of agonists of endothelin-1 exhibiting selectivity towards ETA receptors.

Authors:  Chantal Langlois; Myriam Létourneau; Philipe Lampron; Véronique St-Hilaire; Alain Fournier
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

8.  Expression of endothelin 1 and its receptors in the hypoxic pregnant rat.

Authors:  Larry G Thaete; Tamas Jilling; Sylvia Synowiec; Saira Khan; Mark G Neerhof
Journal:  Biol Reprod       Date:  2007-06-06       Impact factor: 4.285

9.  Altered endothelin receptor binding in response to nitric oxide synthase inhibition in the pregnant rat.

Authors:  Mark G Neerhof; Tamas Jilling; Sylvia Synowiec; Saira Khan; Larry G Thaete
Journal:  Reprod Sci       Date:  2008-03-06       Impact factor: 3.060

10.  Endothelin receptors as novel targets in tumor therapy.

Authors:  Anna Bagnato; Pier Giorgio Natali
Journal:  J Transl Med       Date:  2004-05-27       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.